Illumina to Present at the Piper Jaffray "Unplugged" Health Care Conference

Related Quotes

Symbol	Price	Change
ILMN	35.83	+0.16

{"s" : "ilmn","k" : "c10,l10,p20,t10","o" : "","j" : ""}

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN - News) announced today that the company will webcast its presentation at the Piper Jaffray “Unplugged” Health Care Conference in New York, New York, on December 2, 2009. The live webcast is scheduled to begin at 11:00a.m. ET and will feature a brief overview of the company by Christian Henry, chief financial officer and senior vice president of Corporate Development, followed by a question and answer session.

The live webcast can be accessed under the "Corporate/Investor Information" tab of Illumina's web site at www.illumina.com.

About Illumina

Illumina (www.illumina.com) is the leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) our ability to manufacture robust instrumentation and reagents technology, and (iii) reductions in the funding levels to our primary customers, including as the result of timing and amount of funding provided by the American Recovery and Reinvestment Act of 2009, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any obligation to and do not intend to update any forward-looking statements after the date of this release.

Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com